RVG29 is a peptide derived from rabies virus glycoprotein regions known to interact with neural receptors. The sequence contains aromatic and basic residues that support membrane association and receptor recognition. Researchers use it to study peptide-mediated transport across neural barriers. Applications include targeting-motif characterization, peptide-receptor modeling, and delivery-platform development.
RVG29 is a synthetic peptide derived from the rabies virus glycoprotein, designed for targeted delivery applications in biochemical and neuroscience research. As a 29-amino acid sequence corresponding to a specific domain of the rabies virus glycoprotein, RVG29 exhibits unique affinity for the nicotinic acetylcholine receptor (nAChR) present on neuronal cell membranes. This property has made the peptide an invaluable tool for the development of brain-targeted delivery systems, enabling researchers to explore and manipulate molecular transport across the blood-brain barrier (BBB). Its specificity and functional relevance have positioned RVG29 at the forefront of studies aiming to enhance the precision and efficacy of central nervous system (CNS) research tools.
Targeted delivery system development: RVG29 is widely employed in the design and optimization of nanoparticle and liposome-based drug delivery systems intended for CNS applications. By conjugating the peptide to the surface of various nanocarriers, researchers leverage its receptor-mediated transcytosis capabilities to facilitate transport across the BBB. This approach enables the selective delivery of nucleic acids, proteins, or small molecules to neuronal tissues, addressing a central challenge in neuropharmaceutical research and enhancing the potential for precise molecular interventions in brain studies.
Blood-brain barrier transport studies: The peptide serves as a model ligand for investigating mechanisms underlying receptor-mediated endocytosis and transcytosis at the BBB. By using RVG29 in in vitro and in vivo experimental setups, scientists can dissect the interactions between the glycoprotein-derived motif and neuronal receptors, providing insights into the fundamental biology of CNS access. Such studies inform the rational design of next-generation delivery vectors and contribute to a deeper understanding of brain-selective molecular trafficking.
Neuronal targeting validation: RVG29 is utilized as a biochemical probe to validate and quantify the targeting efficiency of delivery platforms engineered for neuronal uptake. By labeling the peptide or its conjugates with fluorescent or radiolabeled markers, researchers can track biodistribution, cellular uptake, and receptor engagement in complex biological environments. These validation studies are essential for benchmarking the specificity and performance of emerging CNS delivery technologies.
Peptide-receptor interaction analysis: The sequence-specific binding affinity of RVG29 for neuronal nAChRs makes it a valuable tool for studying ligand-receptor interactions at the molecular level. Researchers employ the peptide in binding assays, surface plasmon resonance, and other biophysical techniques to characterize the kinetics and structural determinants of receptor engagement. Such analyses contribute to the broader understanding of neuroreceptor pharmacology and inform the design of synthetic ligands with tailored selectivity.
Peptide engineering and functionalization research: RVG29 provides a robust template for the development and testing of modified peptides with altered targeting properties or enhanced stability. Through systematic sequence modifications, conjugation strategies, or incorporation into multifunctional constructs, scientists utilize the peptide as a starting point to engineer next-generation targeting motifs. These efforts support the advancement of customizable delivery systems for a variety of CNS research applications, driving innovation in neurobiological tool development and molecular engineering.
2. Implications of ligand-receptor binding kinetics on GLP-1R signalling
4. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More